A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Martin, C, Samonigg, H, Kubista, E, Gnant, M EJC SUPPL. 2009, 7(3): 3-3.

Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Marth, C, Samonigg, H, Kubista, E, Gnant, M CANCER RES. 2009, 69(24): 564S-564S.

Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, G, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R BREAST. 2009, 18: S59-S59.

Hodgkin lymphoma in Tyrol-a population-based study.

Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A. Ann Hematol. 2009 May,88(5):449-56. doi: 10.1007/s00277-008-0618-1. Epub 2008 Oct 10.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R N Engl J Med. 2009 Feb 12,360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28,360(22):2379.

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R Onkologie. 2009 Feb,32(1-2):18-24. doi: 10.1159/000180915. Epub 2009 Jan 20.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

Ludwig H, Hajek R, TГіthovГЎ E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Blood. 2009 Apr 9,113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.

The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.

Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP. Cancer Lett. 2009 Jan 8,273(1):127-39. doi: 10.1016/j.canlet.2008.07.029. Epub 2008 Sep 7.

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.

Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B. Eur J Surg Oncol. 2009 Oct,35(10):1048-54. doi: 10.1016/j.ejso.2009.01.014. Epub 2009 Feb 27.

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Lin NU, DiГ©ras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, RochГ© H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, et al. Clin Cancer Res. 2009 Feb 15,15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.